Clinical Scorecard: FDA revises monitoring for SCLC therapy
At a Glance
| Category | Detail |
|---|---|
| Condition | Extensive-stage small cell lung cancer |
| Key Mechanisms | Tarlatamab binds DLL3 on tumor cells and CD3 on T cells, activating T cells to target DLL3-expressing small cell lung cancer cells. |
| Target Population | Adult patients with extensive-stage small cell lung cancer with disease progression on or following platinum-based chemotherapy. |
| Care Setting | Health care setting for monitoring after tarlatamab infusions. |
Key Highlights
- Monitoring reduced from 22-24 hours to 6-8 hours after the first 2 doses.
- Assessment of vital signs required the day after each of the first 2 doses.
- Monitoring periods decrease with subsequent cycles: 3-4 hours for cycles 3 and 4, 2 hours for cycle 5 and beyond.
- Cytokine release syndrome occurred in 57% of patients, with 2% experiencing grade 3 events.
- Neurologic toxicity occurred in 65% of patients, with 7% experiencing grade 3 or higher events.
Guideline-Based Recommendations
Diagnosis
Management
- Monitor patients for 6-8 hours after the first 2 doses of tarlatamab.
- Patients should remain within 1 hour of a health care setting for 48 hours after doses on cycle 1, days 1 and 8.
Monitoring & Follow-up
- Vital signs assessment required the day after each of the first 2 doses.
- Monitoring periods decrease with subsequent doses.
Risks
- Cytokine release syndrome, neurologic toxicity, cytopenias, infections, hepatotoxicity, hypersensitivity reactions, and embryo-fetal toxicity.
Patient & Prescribing Data
Adult patients with extensive-stage small cell lung cancer.
Tarlatamab is administered as a 1-hour intravenous infusion using a step-up dosing schedule.
Clinical Best Practices
- Ensure appropriate monitoring in a health care setting after tarlatamab infusions.
- Educate patients about the signs and symptoms of cytokine release syndrome and neurologic toxicity.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
